Yet another blood pressure medication has been added to the list of recalled hypertension drugs.
Mylan Pharmaceuticals has voluntarily expanded its recall for its valsartan-containing products, the U.S. Food and Drug Administration announced.
The affected pills include valsartan, amlodipine/valsartan and valsartan/hydrochlorothiazide tablets and were distributed in the United States between March 2017 and November 2018. The FDA has listed additional information about the specifics, including doses, lot numbers and expiration dates, on its site.
Scroll down to continue reading
More news from KIRO 7
- KCSO reaches settlement in case where plain-clothed detective pulled gun on motorcyclist
- Seattle man's cyberstalking campaign against former friend and co-worker leads to prison time
- Arson destroys Jehovah's Witnesses hall in Lacey
- Crews respond to fire at Elephant Car Wash in Bellevue
- Do you have an investigative story tip? Send us an email at investigate@kiro7.com
According to the press release, the drugs contain traces of N-nitroso-diethylamine (NDEA). The impurity, typically found in certain foods, drinking water and air pollution, has been classified as a human carcinogen by the International Agency for Research on Cancer.
Mylan is notifying its distributors and customers by letter and is arranging for the return of all recalled products. It is also coordinating returns with retailers, wholesalers and consumers.
Patients on the medications are advised to continue taking the tablets and to contact their doctor for advice. The company said, “the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment.”
The agency recently recalled several other blood pressure medications due to cancer concerns, and another was recalled for mislabeling.
Cox Media Group